Valeant Pharmaceuticals Intl Inc

Cornelia Mascio
Marzo 21, 2017

Stifel Nicolaus reiterated a "buy" rating and issued a $45.00 price target on shares of Valeant Pharmaceuticals Intl in a research note on Thursday, February 9th. Analysts' recommendations are the fountainhead of equity research reports and should be used in tangent with proprietary research and investment methodologies in order to make investment decisions.

Valeant Pharmaceuticals International, Inc.'s (NYSE:VRX) wholly owned subsidiary Bausch + Lomb, a leading global eye health company announced the introduction of Biotrue® ONEday for Astigmatism daily disposable contact lenses.

Average price target for Valeant Pharmaceuticals International, Inc.

When we look at the Analyst Recommendations of the stock, the company has 1 rating given by Analysts where 1 stands for Strong Buy and 5 stands for Strong Sell.

Many research firms have provided their ratings on Valeant Pharmaceuticals International, Inc. Out of rating recommendations 3 have given the stock a Buy while 0 recommend the stock as Outperform.

When it comes to the Analysis of a Stock, Price Target plays a vital role.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) opened at 11.03 on Tuesday. The stock volatility for week was 5.13% while for month was 5.80%.The stock, as of last close, traded 5.05% to its 52 week low and was changed -71.35% from its 52 week high. The stock's 50 day moving average price is $13.98 and its 200-day moving average price is $18.38. The average volume stands around 17.99 million shares. (VRX) reported its last quarter results on 02/28/2017. (VRX) reported the earnings of $1.26/Share in the last quarter where the estimated EPS by analysts was $1.21/share. Valeant Pharmaceuticals Intl had a positive return on equity of 43.81% and a negative net margin of 22.17%.

Many Analysts provided their foresight on Revenue Estimates of Valeant Pharmaceuticals International, Inc. where they believe that the company has the potential to earn average revenue of $2.17 Billion for the current quarter. The Next Year EPS growth is 17%, Long term annual growth estimate of 12.95%, Annual EPS growth past 5 years of 12.66 percent. The business's revenue was down 12.9% compared to the same quarter a year ago. Valeant Pharmaceuticals Intl's revenue was down 12.9% on a year-over-year basis.

In related news, Director Schutter Richard U. De purchased 10,000 shares of the business's stock in a transaction on Wednesday, March 15th. The consensus target price is $25.75 with 1 broker rating the stock a strong buy, 0 brokers rating the stock a buy, 5 brokerages rating the company a hold, one brokerage rating the company a underperform, and lastly zero brokerages rating the company a sell. Following the completion of the purchase, the director now directly owns 25,190 shares in the company, valued at approximately $272,052. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Different analysts and financial institutions use various valuation methods and consider different economic forces when deciding on a price target. They now have a Dollars 17 price target on the stock. The disclosure for this sale can be found here. If you are investing like Buffett, the report can assist in finding the company with the durable competitive advantage, and if Peter Lynch is your hero, you might find a low P/E ratio, share buyback or future earnings growth in the depths of the report. The stock has relative volume of 1.92. TX increased its stake in shares of Valeant Pharmaceuticals Intl by 13.4% in the third quarter. Finally, Arrowstreet Capital Limited Partnership bought a new position in Valeant Pharmaceuticals Intl during the fourth quarter worth $8,495,000. For the next 5 years, Valeant Pharmaceuticals International, expecting Growth of 12.95% per annum, whereas in the past 5 years the growth was 12.66% per annum.

The company's ATR (Average True Range) is 0.89.

Altre relazioniGrafFiotech

Discuti questo articolo

Segui i nostri GIORNALE